Business Description
4D Molecular Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US35104E1001
Share Class Description:
FDMT: Ordinary SharesDescription
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.65 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 20.88 | |||||
| Beneish M-Score | 2.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -37 | |||||
| 3-Year EBITDA Growth Rate | 31.7 | |||||
| 3-Year EPS without NRI Growth Rate | 33.6 | |||||
| 3-Year FCF Growth Rate | 37.1 | |||||
| 3-Year Book Growth Rate | -9.4 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.81 | |||||
| 9-Day RSI | 28.21 | |||||
| 14-Day RSI | 33.56 | |||||
| 6-1 Month Momentum % | 221.23 | |||||
| 12-1 Month Momentum % | 65.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 15.65 | |||||
| Quick Ratio | 15.65 | |||||
| Cash Ratio | 15.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.3 | |||||
| Shareholder Yield % | -12.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -544.68 | |||||
| Net Margin % | -486.62 | |||||
| FCF Margin % | -379.13 | |||||
| ROE % | -35.69 | |||||
| ROA % | -32.32 | |||||
| ROIC % | -272.54 | |||||
| ROC (Joel Greenblatt) % | -336.59 | |||||
| ROCE % | -38.08 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 47.06 | |||||
| PB Ratio | 3.25 | |||||
| Price-to-Tangible-Book | 3.25 | |||||
| EV-to-EBIT | -8.24 | |||||
| EV-to-EBITDA | -8.68 | |||||
| EV-to-Revenue | 44.89 | |||||
| EV-to-Forward-Revenue | 572.41 | |||||
| EV-to-FCF | -11.84 | |||||
| Price-to-Net-Current-Asset-Value | 3.79 | |||||
| Price-to-Net-Cash | 3.91 | |||||
| Earnings Yield (Greenblatt) % | -12.14 | |||||
| FCF Yield % | -6.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FDMT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
4D Molecular Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.722 | ||
| EPS (TTM) ($) | -2.66 | ||
| Beta | 2.92 | ||
| Volatility % | 94.87 | ||
| 14-Day RSI | 33.56 | ||
| 14-Day ATR ($) | 1.673875 | ||
| 20-Day SMA ($) | 26.477 | ||
| 12-1 Month Momentum % | 65.53 | ||
| 52-Week Range ($) | 9.44 - 36.25 | ||
| Shares Outstanding (Mil) | 51.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
4D Molecular Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4D Molecular Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
4D Molecular Therapeutics Inc Frequently Asked Questions
What is 4D Molecular Therapeutics Inc(FDMT)'s stock price today?
The current price of FDMT is $23.25. The 52 week high of FDMT is $36.25 and 52 week low is $9.44.
When is next earnings date of 4D Molecular Therapeutics Inc(FDMT)?
The next earnings date of 4D Molecular Therapeutics Inc(FDMT) is 2024-05-10 Est..
Does 4D Molecular Therapeutics Inc(FDMT) pay dividends? If so, how much?
4D Molecular Therapeutics Inc(FDMT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers